Clinton Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Clinton Group’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,535	Closed	-$998K	–	522
2017 Q4	$998K	Buy	+9,535	New	+$1.05M	0.09%	251
2017 Q3	–	Sell	-5,598	Closed	-$627K	–	635
2017 Q2	$627K	Buy	+5,598	New	+$632K	0.06%	365
2017 Q1	–	Sell	-46,370	Closed	-$4.88M	–	1075
2016 Q4	$4.88M	Sell	46,370 -13,512	-23%	-$1.42M	0.28%	104
2016 Q3	$6.62M	Buy	+59,882	New	+$7.93M	0.31%	87
2015 Q2	–	Sell	-5,706	Closed	-$805K	–	732
2015 Q1	$805K	Buy	+5,706	New	+$878K	0.21%	141

Other funds holding TARO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Fort LP Chevy Chase, Maryland $39.6M AUM 37.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Clinton Group's TARO Position: Q1 2018 in Review

Clinton Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2018, closing a stake of 9,535 shares — an estimated $998K sold.

Clinton Group first reported a position in TARO in Q1 2015 and held it in 5 quarters. The position peaked at $6.62M in Q3 2016. 109 funds tracked by Wall St. Rank hold TARO as of Q1 2018.

Clinton Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2018 after selling out during the quarter.
Clinton Group sold 9,535 Taro Pharmaceutical Industries Ltd. shares in Q1 2018, an estimated $998K.
Clinton Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2015 and held it in 5 quarters.
Clinton Group's Taro Pharmaceutical Industries Ltd. position peaked at $6.62M in Q3 2016.
109 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2018.

Based on Clinton Group's 13F filing for Q1 2018, filed 14 May 2018.